Literature DB >> 15022031

P-glycoprotein function in the elderly.

Stefanie S Brenner1, Ulrich Klotz.   

Abstract

OBJECTIVE: The MDR1-encoded P-glycoprotein (Pgp) represents the best-studied membraneous efflux pump defending the body against xenobiotics. Various polymorphisms (single nucleotide polymorphisms; SNPs) in the MDR1 gene have been identified, and a silent mutation in exon 26 (C3435T) has been correlated with duodenal expression of Pgp, which might affect the disposition of certain drugs. The C3435T SNP has been shown to be linked to another SNP (G2677T/A) in exon 21 which leads to an amino acid exchange. So far, the influence of age on Pgp function has been neglected. As the function of Pgp might be altered in advanced age, we investigated in groups of fit and frail elderly subjects whether the efflux of the Pgp-probe rhodamine 123 from CD56(+) natural killer cells was age dependent and whether it was affected by the two SNPs.
METHODS: Leukocytes were isolated from blood of 18 healthy elderly subjects (mean age 69 years) and 20 geriatric frail patients (mean age 78 years) and data compared with 21 previously studied young healthy Caucasian individuals (mean age 33 years). Subjects were homozygous for either CC- or TT-genotype (SNP C3435T) and additionally differentiated according to genotype GG or TT of the SNP G2677T. Using flow cytometry, rhodamine fluorescence was monitored in CD56(+) cells.
RESULTS: In contrast to the young controls, in both elderly populations no significant difference between the CC and TT genotypes (exon 26) could be observed in rhodamine fluorescence. Furthermore, only for the TT genotype (exon 26) did frail elderly demonstrate some reduced Pgp function ( P=0.03) if compared with the young healthy subjects. If the three groups were compared independent of the genotype, no age effects were observed. For all assessed genotypes, there was no significant difference between fit and frail elderly subjects.
CONCLUSION: Aging and frailty have apparently only a minor impact on this validated cellular Pgp model and it could be assumed that function of Pgp is quite well preserved in patients of advanced age.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15022031     DOI: 10.1007/s00228-004-0733-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  39 in total

1.  Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes.

Authors:  C G Machado; R T Calado; A B Garcia; R P Falcão
Journal:  Braz J Med Biol Res       Date:  2003-11-17       Impact factor: 2.590

2.  MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences.

Authors:  Richard B Kim
Journal:  Pharmacogenetics       Date:  2002-08

3.  Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833.

Authors:  R Robey; S Bakke; W Stein; B Meadows; T Litman; S Patil; T Smith; T Fojo; S Bates
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

Review 4.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects.

Authors:  Yoshinori Morita; Toshiyuki Sakaeda; Masanori Horinouchi; Tsutomu Nakamura; Kohei Kuroda; Ikuya Miki; Ken Yoshimura; Toshiyuki Sakai; Daisuke Shirasaka; Takao Tamura; Nobuo Aoyama; Masato Kasuga; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

6.  MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes.

Authors:  Kersti Oselin; Thomas Gerloff; Przemyslaw M Mrozikiewicz; Rein Pähkla; Ivar Roots
Journal:  Fundam Clin Pharmacol       Date:  2003-08       Impact factor: 2.748

Review 7.  P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy.

Authors:  S Gupta
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

8.  Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.

Authors:  Taku Furuno; Maria-Teresa Landi; Mauro Ceroni; Neil Caporaso; Ilaria Bernucci; Giuseppe Nappi; Emilia Martignoni; Elke Schaeffeler; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Pharmacogenetics       Date:  2002-10

9.  Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.

Authors:  Yasuo Kurata; Ichiro Ieiri; Miyuki Kimura; Toshihiro Morita; Shin Irie; Akinori Urae; Shigehiro Ohdo; Hisakazu Ohtani; Yasufumi Sawada; Shun Higuchi; Kenji Otsubo
Journal:  Clin Pharmacol Ther       Date:  2002-08       Impact factor: 6.875

Review 10.  P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection.

Authors:  S Gupta; S Gollapudi
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

View more
  11 in total

Review 1.  Predicting and preventing adverse drug reactions in the very old.

Authors:  Louis Merle; Marie-Laure Laroche; Thierry Dantoine; Jean-Pierre Charmes
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

Review 4.  Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population.

Authors:  Ronald N Hines; Dana Sargent; Herman Autrup; Linda S Birnbaum; Robert L Brent; Nancy G Doerrer; Elaine A Cohen Hubal; Daland R Juberg; Christian Laurent; Robert Luebke; Klaus Olejniczak; Christopher J Portier; William Slikker
Journal:  Toxicol Sci       Date:  2009-09-21       Impact factor: 4.849

Review 5.  Sensitivity to antipsychotic drugs in older adults.

Authors:  Chloe Leon; Philip Gerretsen; Hiroyuki Uchida; Takefumi Suzuki; Tarek Rajji; David C Mamo
Journal:  Curr Psychiatry Rep       Date:  2010-02       Impact factor: 5.285

6.  Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells.

Authors:  Caroline Henrike Storch; Hans-Dieter Klimm; Tilman Heinrich; Walter Emil Haefeli; Johanna Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-07-26       Impact factor: 3.000

Review 7.  A Rationale for Age-Adapted Immunosuppression in Organ Transplantation.

Authors:  Felix Krenzien; Abdallah ElKhal; Markus Quante; Hector Rodriguez Cetina Biefer; Uehara Hirofumi; Steven Gabardi; Stefan G Tullius
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

8.  The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients.

Authors:  Charalampos Dragonas; Jan T Wagner; Hans J Heppner; Thomas Bertsch; Wolfgang Muhlberg; Susanne Wicklein; Andreas Pahl; Christine Diewald; Iouri Bachmakov; Cornel C Sieber; Martin F Fromm
Journal:  Eur J Clin Pharmacol       Date:  2007-12-16       Impact factor: 2.953

9.  Clinical implications of changes in hepatic drug metabolism in older people.

Authors:  Sarah N Hilmer; Gillian M Shenfield; David G Le Couteur
Journal:  Ther Clin Risk Manag       Date:  2005-06       Impact factor: 2.423

Review 10.  What do we know about frailty in the acute care setting? A scoping review.

Authors:  Olga Theou; Emma Squires; Kayla Mallery; Jacques S Lee; Sherri Fay; Judah Goldstein; Joshua J Armstrong; Kenneth Rockwood
Journal:  BMC Geriatr       Date:  2018-06-11       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.